WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.

IF 2.8 4区 医学 Q2 ONCOLOGY Medical Oncology Pub Date : 2024-05-14 DOI:10.1007/s12032-024-02388-4
Jinfeng Cheng, Dan Huo, Zhonghua Zhang, Jianqing Zhang, Bizhen Dong, Zhen Liu, Zhi Zhou, Yanjun Lu
{"title":"WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.","authors":"Jinfeng Cheng, Dan Huo, Zhonghua Zhang, Jianqing Zhang, Bizhen Dong, Zhen Liu, Zhi Zhou, Yanjun Lu","doi":"10.1007/s12032-024-02388-4","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer-related death among men. A comprehensive understanding of PCa progression is crucial for the development of innovative therapeutic strategies for its treatment. While WDR1 (WD-repeat domain 1) serves as a significant cofactor of actin-depolymerizing factor/cofilin, its role in PCa progression remains unknown. In this study, we demonstrated that knockdown of WDR1 in various PCa cells substantially inhibited cell proliferation, migration, and invasion in vitro, as confirmed at both the cellular and molecular levels. Moreover, the overexpression of WDR1 promoted PCa cell proliferation and metastasis in vitro. Mechanistically, we showed that the application of lithium chloride, an activator of the Wnt/β-Catenin signaling pathway, restored the suppressive effects of WDR1 deficiency on cell proliferation and migration in PCa cells. Our findings suggest that the WDR1-β-Catenin axis functions as an activator of the malignant phenotype and represents a promising therapeutic target for PCa treatment.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02388-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer-related death among men. A comprehensive understanding of PCa progression is crucial for the development of innovative therapeutic strategies for its treatment. While WDR1 (WD-repeat domain 1) serves as a significant cofactor of actin-depolymerizing factor/cofilin, its role in PCa progression remains unknown. In this study, we demonstrated that knockdown of WDR1 in various PCa cells substantially inhibited cell proliferation, migration, and invasion in vitro, as confirmed at both the cellular and molecular levels. Moreover, the overexpression of WDR1 promoted PCa cell proliferation and metastasis in vitro. Mechanistically, we showed that the application of lithium chloride, an activator of the Wnt/β-Catenin signaling pathway, restored the suppressive effects of WDR1 deficiency on cell proliferation and migration in PCa cells. Our findings suggest that the WDR1-β-Catenin axis functions as an activator of the malignant phenotype and represents a promising therapeutic target for PCa treatment.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
WDR1 通过 Wnt/β-catenin 信号促进前列腺癌的进展。
前列腺癌(PCa)是第二大常见癌症,也是导致男性癌症相关死亡的第五大原因。全面了解 PCa 的进展对于开发创新的治疗策略至关重要。虽然 WDR1(WD-重复结构域 1)是肌动蛋白解聚因子/纤维蛋白的重要辅助因子,但它在 PCa 进展中的作用仍不清楚。在本研究中,我们证实了在体外敲除各种 PCa 细胞中的 WDR1 能大大抑制细胞的增殖、迁移和侵袭,这在细胞和分子水平上都得到了证实。此外,体外过表达 WDR1 会促进 PCa 细胞的增殖和转移。从机理上讲,我们发现氯化锂(Wnt/β-Catenin 信号通路的激活剂)的应用恢复了 WDR1 缺乏对 PCa 细胞增殖和迁移的抑制作用。我们的研究结果表明,WDR1-β-Catenin轴是恶性表型的激活剂,是治疗PCa的一个很有前景的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
期刊最新文献
Incidence of lymphedema related to various cancers The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review Lipid metabolism reprogramming in renal cell carcinomas. Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review. The role of IL-22 in cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1